GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Biogen Idec Inc (BIIB) [hlAlert]

Rating:
Buy BIIB
up 50.03 %

Biogen Idec Inc (BIIB) upgraded to Buy by BofA/Merrill

Posted on: Friday,  Apr 12, 2013  9:25 AM ET by BofA/Merrill

BofA/Merrill rated Buy Biogen Idec Inc (NASDAQ: BIIB) on 04/12/2013, when the stock price was $202.94. Since
then, Biogen Idec Inc has gained 50.04% as of 01/07/2016's recent price of $304.49.
If you would have followed this BofA/Merrill's recommendation on BIIB, you would have gained 50.03% of your investment in 1000 days.

Biogen Idec Inc. is engaged in the development, manufacturing, and commercialization of therapies. The Company?s products address diseases such as multiple sclerosis, non-Hodgkin?s lymphoma (NHL), rheumatoid arthritis (RA), crohn?s disease (CD) and psoriasis. The Company has four products: AVONEX (interferon beta-1a), RITUXAN (rituximab), TYSABRI (natalizumab) and FUMADERM (dimethylfumarate and monoethylfumarate salts). AVONEX is used in the treatment of relapsing forms of multiple sclerosis (MS). RITUXAN is one of the selling oncology therapeutics. In the United States, RITUXAN is approved for NHL. TYSABRI is approved for the treatment of relapsing forms of MS. FUMADERM acts as an immunomudulator. The Company also has product candidates, such as BG-12, which is a oral fumarate; ANTI-CD80 monoclonal antibody (MAb)(galiximab); ANTI-CD23 MAb (lumiliximab); Humanized Anti-CD20 MAb (ocrelizumab), Lixivaptan, an oral compound for the potential treatment of hyponatremia, and ADENTRI.

BofA/Merrill
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/12/2013 9:25 AM Buy
None
202.94
as of 12/13/2013
1 Week down  -5.35 %
1 Month up  16.61 %
3 Months up  17.30 %
1 YTD up  35.66 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/15/2013 8:25 AM Hold
None
140.83

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy